CIK 0000939767
- Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043257395
- Phone
- +1 650-837-7000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-26 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion | +40,000 | $4.20 | $168K | 689,078 |
| 2021-07-26 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-07-21 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion | +35,000 | $4.20 | $147K | 649,078 |
| 2021-07-21 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion · Option (right to buy) | −35,000 | 40,000 | ||
| 2021-07-15 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion | +60,000 | $1.90 | $114K | 449,467 |
| 2021-07-15 | Lamb Peter EVP, Scientific Strategy & CSO | Sale | −60,000 | $17.47 | $1.0M | 389,467 |
| 2021-07-15 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion · Option (right to buy) | −60,000 | 55,000 | ||
| 2021-07-06 | COHEN CHARLES Director | Exercise or conversion | +40,000 | $3.13 | $125K | 221,375 |
| 2021-07-06 | COHEN CHARLES Director | Exercise or conversion | +40,000 | $6.30 | $252K | 261,375 |
| 2021-07-06 | COHEN CHARLES Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-07-06 | COHEN CHARLES Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-06-17 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion | +60,000 | $1.90 | $114K | 449,467 |
| 2021-06-17 | Lamb Peter EVP, Scientific Strategy & CSO | Sale | −60,000 | $22.18 | $1.3M | 389,467 |
| 2021-06-17 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion · Option (right to buy) | −60,000 | 115,000 | ||
| 2021-05-27 | WYSZOMIERSKI JACK L Director | Grant or award | +8,299 | 239,888 | ||
| 2021-05-27 | WYSZOMIERSKI JACK L Director | Grant or award · Option (right to buy) | +16,598 | 16,598 | ||
| 2021-05-27 | FELDBAUM CARL B Director | Grant or award · Option (right to buy) | +33,549 | 33,549 | ||
| 2021-05-27 | WILLSEY LANCE Director | Grant or award · Option (right to buy) | +33,549 | 33,549 | ||
| 2021-05-27 | MARCHESI VINCENT T Director | Grant or award | +8,299 | 74,414 | ||
| 2021-05-27 | MARCHESI VINCENT T Director | Grant or award · Option (right to buy) | +16,598 | 16,598 |
Page 31 of 42 · 836 trades